ライフサイエンスコーパス: effective regurgitant orifice

1 e of functional mitral regurgitation (larger effective regurgitant orifice).

2 R augmentation was demonstrated by increased effective regurgitant orifice (0.21 cm(2); 25th to 75th

3 orce, regurgitant volume increased less than effective regurgitant orifice (120 [25th to 75th percent

4 ns (regurgitant volume, 66+/-40 ml per beat; effective regurgitant orifice, 40+/-27 mm2).

5 ge, the presence of diabetes, and increasing effective regurgitant orifice (adjusted risk ratio per 1

6 Direct measurements of the effective regurgitant orifice are also feasible and serv

7 4.7 +/- 2.1 ml to 3.1 +/- 0.5 ml, p < 0.05), effective regurgitant orifice area (0.130 +/- 0.010 cm(2

8 gitant volume (69 +/- 47 to 69 +/- 56 ml) or effective regurgitant orifice area (0.5 +/- 0.4 to 0.5 +

9 Significant reductions in effective regurgitant orifice area (0.9+/-0.3cm(2) versu

10 nificant reduction in annular area (57%) and effective regurgitant orifice area (53%) measured with 3

11 ed, but lower right atrial area and lower TV effective regurgitant orifice area (all P<0.05).

12 evaluate the accuracy of determining aortic effective regurgitant orifice area (EROA) and aortic reg

13 nts with <=moderate chronic AR quantified by effective regurgitant orifice area (EROA) and regurgitan

14 he definition of severe secondary MR from an effective regurgitant orifice area (EROA) of 0.4 to 0.2

15 s of mitral regurgitant flow rate (MRFR) and effective regurgitant orifice area (EROA) on mitral regu

16 directed medical therapy and assessed sMR by effective regurgitant orifice area (EROA), regurgitant v

17 tomatic HF and moderate-to-severe vSMR (mean effective regurgitant orifice area .25 cm2; 14% >.40 cm2

18 ptomatic HF and moderate to severe FMR (mean effective regurgitant orifice area 0.25 cm(2); 14% >0.40

19 Echocardiographic measurements (TA diameter, effective regurgitant orifice area [EROA], left ventricu

20 ve measures of vena contracta and PISA-based effective regurgitant orifice area and regurgitant volum

21 Using an in vitro model of MR, the effective regurgitant orifice area and regurgitant volum

22 VCW, effective regurgitant orifice area and regurgitant volum

23 nitroprusside was concordant with changes in effective regurgitant orifice area and regurgitant volum

24 In patients (n=30, functional MR), 3D effective regurgitant orifice area correlated well with

25 p < 0.01), proximal isovelocity surface area effective regurgitant orifice area of 50% (0.8 cm(2) vs.

26 ship between LV end-diastolic volume and the effective regurgitant orifice area of the mitral valve.

27 nd-diastolic volume was 192.7 +/- 71 ml, and effective regurgitant orifice area was 0.41 +/- 0.15 cm(

28 cuspid valve annular area of 14.1 cm(2), and effective regurgitant orifice area was 1.35 cm(2).

29 The median mitral effective regurgitant orifice area was 26 mm(2) (Q1-Q3:

30 Effective regurgitant orifice area was calculated by div

31 ate and severe primary degenerative MR (mean effective regurgitant orifice area, 0.45 +/- 0.25 cm)(2)

32 ted moderate to severe mitral regurgitation (effective regurgitant orifice area, 38+/-18 mm(2)) and p

33 ng PISA-based regurgitant volume, PISA-based effective regurgitant orifice area, and vena contracta w

34 SA)-derived regurgitant volume, PISA-derived effective regurgitant orifice area, vena contracta, colo

35 During inspiration, a large increase in effective regurgitant orifice causes, despite a decline

36 Effective regurgitant orifice changes are independently

37 Effective regurgitant orifice during inspiration was ind

38 all P<0.0001) were obtained between VC-W and effective regurgitant orifice (ERO) area and regurgitant

39 IMR patients, regurgitant volume (RVol) and effective regurgitant orifice (ERO) area were 36+/-24 mL

40 Whether effective regurgitant orifice (ERO) by the flow converge

41 The VCW correlated well with the effective regurgitant orifice (ERO) by the flow converge

42 urface area (PISA) method for calculation of effective regurgitant orifice (ERO) of aortic regurgitat

43 ified simultaneously by echocardiography the effective regurgitant orifice (ERO) of FMR by using 2 me

44 volume (RVol), regurgitant fraction (RF) and effective regurgitant orifice (ERO) to define progressio

45 PHTN-FTR and Id-FTR were also matched for TR effective-regurgitant-orifice (ERO).

46 cardiographic quantitation of IMR (measuring effective regurgitant orifice [ERO] and regurgitant volu

47 with DMR quantified prospectively (measuring effective regurgitant orifice [ERO] and regurgitant volu

48 oppler-echocardiographic quantitation of MR (effective regurgitant orifice [ERO]) and left ventricula

49 ntricular end-systolic dimension, and mitral effective regurgitant orifice increased the C-statistic

50 , left ventricular ejection fraction, mitral effective regurgitant orifice, indexed LV end-diastolic

51 Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic d

52 Patients with an effective regurgitant orifice of at least 40 mm2 had a f

53 Patients with an effective regurgitant orifice of at least 40 mm2 should

54 if < 150 ms, 48.8 [14.8 to 161]) and mitral effective regurgitant orifice (r = 0.50, p = 0.0001; odd

55 g left ventricular ejection fraction, mitral effective regurgitant orifice, resting right ventricular

56 Mitral effective regurgitant orifice size (n=84) influenced RV

57 flow rate could be determined from the known effective regurgitant orifice times the orifice velocity

58 and correlation with angiographic grades for effective regurgitant orifice were 43+/-37 mm and r=.79